PH12016501975A1 - New use of n,n-bis-2-mercaptoethyl isophthalamide - Google Patents

New use of n,n-bis-2-mercaptoethyl isophthalamide

Info

Publication number
PH12016501975A1
PH12016501975A1 PH12016501975A PH12016501975A PH12016501975A1 PH 12016501975 A1 PH12016501975 A1 PH 12016501975A1 PH 12016501975 A PH12016501975 A PH 12016501975A PH 12016501975 A PH12016501975 A PH 12016501975A PH 12016501975 A1 PH12016501975 A1 PH 12016501975A1
Authority
PH
Philippines
Prior art keywords
bis
new use
mercaptoethyl isophthalamide
isophthalamide
mercaptoethyl
Prior art date
Application number
PH12016501975A
Other languages
English (en)
Inventor
Haley Boyd Eugene
Klingberg Ragnar Axel Theodor
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50776843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of PH12016501975A1 publication Critical patent/PH12016501975A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12016501975A 2014-04-04 2016-10-04 New use of n,n-bis-2-mercaptoethyl isophthalamide PH12016501975A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1406115.4A GB2524831A (en) 2014-04-04 2014-04-04 New pharmaceutical use
PCT/GB2015/050999 WO2015150793A1 (en) 2014-04-04 2015-03-31 New use of n,n-bis-2-mercaptoethyl isophthalamide

Publications (1)

Publication Number Publication Date
PH12016501975A1 true PH12016501975A1 (en) 2017-01-09

Family

ID=50776843

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501975A PH12016501975A1 (en) 2014-04-04 2016-10-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Country Status (36)

Country Link
US (1) US9782368B2 (enExample)
EP (1) EP3125876B8 (enExample)
JP (1) JP6474423B2 (enExample)
KR (1) KR102482699B1 (enExample)
CN (1) CN106132405B (enExample)
AU (1) AU2015242374B2 (enExample)
BR (1) BR112016022880B1 (enExample)
CA (1) CA2944113C (enExample)
CL (1) CL2016002499A1 (enExample)
CY (1) CY1121235T1 (enExample)
DK (1) DK3125876T3 (enExample)
EA (1) EA032116B1 (enExample)
EC (1) ECSP16078100A (enExample)
ES (1) ES2659174T3 (enExample)
GB (1) GB2524831A (enExample)
HR (1) HRP20180325T1 (enExample)
HU (1) HUE036206T2 (enExample)
IL (1) IL248027B (enExample)
LT (1) LT3125876T (enExample)
MA (1) MA39833B1 (enExample)
ME (1) ME03012B (enExample)
MX (1) MX2016012591A (enExample)
NO (1) NO3125876T3 (enExample)
NZ (1) NZ724678A (enExample)
PE (1) PE20170586A1 (enExample)
PH (1) PH12016501975A1 (enExample)
PL (1) PL3125876T3 (enExample)
PT (1) PT3125876T (enExample)
RS (1) RS56905B1 (enExample)
SA (1) SA516371966B1 (enExample)
SG (1) SG11201607478RA (enExample)
SI (1) SI3125876T1 (enExample)
SM (1) SMT201800116T1 (enExample)
UA (1) UA119558C2 (enExample)
WO (1) WO2015150793A1 (enExample)
ZA (1) ZA201606406B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use
CN114778234B (zh) * 2022-03-18 2025-08-15 武汉新烽光电股份有限公司 一种用于微流控总磷测试的抗坏血酸溶液的保存方法及保存结构

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
JP2011026204A (ja) * 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び/又は治療用組成物
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
JP2013505963A (ja) * 2009-09-28 2013-02-21 ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデイション 汚染された環境から元素を除去するチオール含有化合物およびその使用方法
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) * 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Also Published As

Publication number Publication date
BR112016022880B1 (pt) 2022-09-13
SA516371966B1 (ar) 2019-04-14
EP3125876B1 (en) 2017-11-29
US20170157072A1 (en) 2017-06-08
CN106132405A (zh) 2016-11-16
AU2015242374A1 (en) 2016-10-13
PE20170586A1 (es) 2017-05-20
US9782368B2 (en) 2017-10-10
MX2016012591A (es) 2017-04-06
SMT201800116T1 (it) 2018-03-08
AU2015242374B2 (en) 2019-10-10
JP2017511307A (ja) 2017-04-20
CN106132405B (zh) 2019-06-18
SG11201607478RA (en) 2016-10-28
CY1121235T1 (el) 2020-05-29
HRP20180325T1 (hr) 2018-04-06
NZ724678A (en) 2022-12-23
EA201692013A1 (ru) 2017-03-31
ZA201606406B (en) 2018-04-25
GB201406115D0 (en) 2014-05-21
UA119558C2 (uk) 2019-07-10
MA39833B1 (fr) 2018-04-30
CA2944113C (en) 2022-06-21
NO3125876T3 (enExample) 2018-04-28
CA2944113A1 (en) 2015-10-08
DK3125876T3 (en) 2018-01-15
EP3125876B8 (en) 2018-01-24
ECSP16078100A (es) 2018-03-31
MA39833A (fr) 2017-02-08
WO2015150793A1 (en) 2015-10-08
KR102482699B1 (ko) 2022-12-28
KR20160140929A (ko) 2016-12-07
EA032116B1 (ru) 2019-04-30
GB2524831A (en) 2015-10-07
SI3125876T1 (en) 2018-04-30
ES2659174T3 (es) 2018-03-14
HUE036206T2 (hu) 2018-06-28
BR112016022880A2 (enExample) 2017-08-15
CL2016002499A1 (es) 2017-01-27
EP3125876A1 (en) 2017-02-08
PT3125876T (pt) 2018-02-22
LT3125876T (lt) 2018-02-12
PL3125876T3 (pl) 2018-05-30
ME03012B (me) 2018-10-20
JP6474423B2 (ja) 2019-02-27
RS56905B1 (sr) 2018-05-31
IL248027B (en) 2019-03-31

Similar Documents

Publication Publication Date Title
MX387115B (es) Métodos para tratar la influenza.
JP2016515522A5 (enExample)
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
MY199131A (en) Human plasma kallikrein inhibitors
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
IL240931A0 (en) History 3 - Phenylpropylamine is converted to the treatment of eye diseases and disorders
HK1245078A1 (zh) 治疗神经退行性疾病的方法
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
IL256329B (en) Carbazole derivatives for the treatment of fibrotic diseases, symptoms and conditions related to them
PH12016501975A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
JO3609B1 (ar) علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ITUB20153076A1 (it) Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento.
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
PH12018500221A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA93635U (uk) Фармацевтична композиція для лікування хронічних обструктивних захворювань легень